These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Bioinformatic and functional optimization of antisense phosphorodiamidate morpholino oligomers (PMOs) for therapeutic modulation of RNA splicing in muscle. Popplewell LJ; Graham IR; Malerba A; Dickson G Methods Mol Biol; 2011; 709():153-78. PubMed ID: 21194027 [TBL] [Abstract][Full Text] [Related]
3. DMD pseudoexon mutations: splicing efficiency, phenotype, and potential therapy. Gurvich OL; Tuohy TM; Howard MT; Finkel RS; Medne L; Anderson CB; Weiss RB; Wilton SD; Flanigan KM Ann Neurol; 2008 Jan; 63(1):81-9. PubMed ID: 18059005 [TBL] [Abstract][Full Text] [Related]
4. Direct Reprogramming of Human DMD Fibroblasts into Myotubes for In Vitro Evaluation of Antisense-Mediated Exon Skipping and Exons 45-55 Skipping Accompanied by Rescue of Dystrophin Expression. Lee JJA; Saito T; Duddy W; Takeda S; Yokota T Methods Mol Biol; 2018; 1828():141-150. PubMed ID: 30171539 [TBL] [Abstract][Full Text] [Related]
12. Towards a therapeutic inhibition of dystrophin exon 23 splicing in mdx mouse muscle induced by antisense oligoribonucleotides (splicomers): target sequence optimisation using oligonucleotide arrays. Graham IR; Hill VJ; Manoharan M; Inamati GB; Dickson G J Gene Med; 2004 Oct; 6(10):1149-58. PubMed ID: 15386737 [TBL] [Abstract][Full Text] [Related]
13. Neuronal SH-SY5Y cells use the C-dystrophin promoter coupled with exon 78 skipping and display multiple patterns of alternative splicing including two intronic insertion events. Nishida A; Minegishi M; Takeuchi A; Awano H; Niba ET; Matsuo M Hum Genet; 2015 Sep; 134(9):993-1001. PubMed ID: 26152642 [TBL] [Abstract][Full Text] [Related]
14. In Vivo Evaluation of Multiple Exon Skipping with Peptide-PMOs in Cardiac and Skeletal Muscles in Dystrophic Dogs. Maruyama R; Aoki Y; Takeda S; Yokota T Methods Mol Biol; 2018; 1828():365-379. PubMed ID: 30171554 [TBL] [Abstract][Full Text] [Related]
15. Circular dystrophin RNAs consisting of exons that were skipped by alternative splicing. Surono A; Takeshima Y; Wibawa T; Ikezawa M; Nonaka I; Matsuo M Hum Mol Genet; 1999 Mar; 8(3):493-500. PubMed ID: 9949208 [TBL] [Abstract][Full Text] [Related]
16. A novel human muscle cell model of Duchenne muscular dystrophy created by CRISPR/Cas9 and evaluation of antisense-mediated exon skipping. Shimo T; Hosoki K; Nakatsuji Y; Yokota T; Obika S J Hum Genet; 2018 Mar; 63(3):365-375. PubMed ID: 29339778 [TBL] [Abstract][Full Text] [Related]
17. Triple trans-splicing adeno-associated virus vectors capable of transferring the coding sequence for full-length dystrophin protein into dystrophic mice. Koo T; Popplewell L; Athanasopoulos T; Dickson G Hum Gene Ther; 2014 Feb; 25(2):98-108. PubMed ID: 24191945 [TBL] [Abstract][Full Text] [Related]
18. Creation of DMD Muscle Cell Model Using CRISPR-Cas9 Genome Editing to Test the Efficacy of Antisense-Mediated Exon Skipping. Maruyama R; Yokota T Methods Mol Biol; 2018; 1828():165-171. PubMed ID: 30171541 [TBL] [Abstract][Full Text] [Related]
19. Target selection for antisense oligonucleotide induced exon skipping in the dystrophin gene. Errington SJ; Mann CJ; Fletcher S; Wilton SD J Gene Med; 2003 Jun; 5(6):518-27. PubMed ID: 12797117 [TBL] [Abstract][Full Text] [Related]
20. Antisense-induced exon skipping restores dystrophin expression in DMD patient derived muscle cells. van Deutekom JC; Bremmer-Bout M; Janson AA; Ginjaar IB; Baas F; den Dunnen JT; van Ommen GJ Hum Mol Genet; 2001 Jul; 10(15):1547-54. PubMed ID: 11468272 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]